Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.

Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, Michel Tod, Sylvain Goutelle

Antimicrobial agents and chemotherapy 2021 Aug 17

filter terms:

Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.

Citation

Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, Michel Tod, Sylvain Goutelle. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrobial agents and chemotherapy. 2021 Aug 17;65(9):e0104321